荣昌生物(688331.SH):抗体偶联药物RC278获得药物临床试验申请受理通知书

智通财经
12 May

智通财经APP讯,荣昌生物(688331.SH)发布公告,近日,公司收到国家药品监督管理局核准签发的《受理通知书》,新型抗体偶联(ADC)药物注射用RC278的临床试验申请获得受理。

RC278是由荣昌生物自主研发的一款具有First-in-Class/Best-in-Class潜质的ADC分子,该分子能特异识别一个新型肿瘤靶点,并具有创新的连接子—毒素系统,在临床前研究中展现出广谱抗肿瘤活性、良好的安全性和药代动力学特征,将为晚期实体瘤患者带来新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10